Clinical Trials

502 enrolled 18 charts 2 FDA

Gynecologic

Uterine Cervical Neoplasms

NCT03088540 2026-02-23

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

712 enrolled 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04221945 2026-02-20

KEYNOTE-A18

1,060 enrolled 30 charts 2 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT02684292 2026-02-18

MK-3475-204

304 enrolled 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease

NCT03332017 2026-02-18

ROSEWOOD

217 enrolled 23 charts 2 FDA

Lymphoma, Follicular

NCT03143153 2026-02-17

CheckMate 648

970 enrolled 15 charts 2 FDA

Various Advanced Cancer

NCT02000622 2026-02-13

OlympiAD

302 enrolled 26 charts 1 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01516580 2026-02-09

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

482 enrolled 2 FDA

Burkitt Lymphoma, Lymphoma, B-Cell

NCT03275285 2026-02-09

IKEMA

302 enrolled 38 charts 2 FDA

Plasma cell

Multiple Myeloma

NCT02122913 2026-02-05

A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

Phase 1 Completed

75 enrolled 3 FDA

Other solid neoplasm

Solid Tumors Harboring NTRK Fusion

NCT03635567 2026-02-04

KEYNOTE-826

617 enrolled 29 charts 2 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT02853331 2026-02-02

KEYNOTE-426

861 enrolled 24 charts 1 FDA

LymphoidOther hematologic neoplasmSarcoma

Carcinoma, Renal Cell

NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Phase 1/2 Completed

803 enrolled 4 FDA

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT04744831 2026-01-14

DESTINY-CRC02

122 enrolled 21 charts 2 FDA

Colorectal Neoplasms

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

608 enrolled 22 charts 2 FDA

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT02998528 2026-01-06

CheckMate 816

505 enrolled 17 charts 2 FDA

657 enrolled 57 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT01658878 2025-12-24

CheckMate040

Phase 1/2 Completed

Carcinoma, Hepatocellular

NCT03105336 2025-12-23

ZUMA-5

159 enrolled 27 charts 2 FDA

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT03180736 2025-12-19

EMN14

304 enrolled 19 charts 2 FDA

Plasma cell

Multiple Myeloma

NCT03215706 2025-12-17

CheckMate 9LA

719 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT01743131 2025-12-11

Abatacept as GVHD Prophylaxis Phase 2

186 enrolled 14 charts 2 FDA

Graft vs Host Disease, Neoplasms

NCT03615326 2025-12-11

MK-3475-811

738 enrolled 22 charts 6 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT03735121 2025-12-05

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

438 enrolled 40 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT02421939 2025-12-04

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

371 enrolled 36 charts 2 FDA

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02799602 2025-12-04

ARASENS

1,306 enrolled 25 charts 4 FDA

Metastatic Hormone-sensitive Prostate Cancer

NCT01358877 2025-11-28

APHINITY

4,804 enrolled 45 charts 1 FDA

Breast

Breast Neoplasms

NCT03201965 2025-11-26

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

416 enrolled 28 charts 4 FDA

Plasma cell

Amyloidosis

NCT02743494 2025-11-18

CheckMate 577

794 enrolled 13 charts 2 FDA

Advanced Cancer

NCT03011372 2025-11-18

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

47 enrolled 21 charts 2 FDA

Myeloid

Eosinophilia, Myeloproliferative Disorders

NCT02576431 2025-11-12

NAVIGATE

BreastDermatologicGastrointestinalHead & NeckSarcomaThoracic

215 enrolled 3 FDA

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Salivary Gland Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms

NCT02060188 2025-11-06

CheckMate142

385 enrolled 17 charts 2 FDA

GastrointestinalOther solid neoplasm

Microsatellite Unstable Colorectal Cancer

NCT02242942 2025-11-06

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

445 enrolled 22 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04472429 2025-11-03

Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

308 enrolled 17 charts 2 FDA

Anus Neoplasms, Carcinoma, Squamous Cell

NCT02477826 2025-10-30

CheckMate 227

2,747 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03036488 2025-10-29

MK-3475-522

1,174 enrolled 2 FDA

Breast

Triple Negative Breast Neoplasms

NCT02677896 2025-10-24

ARCHES

1,150 enrolled 23 charts 1 FDA